CBLB-silencing RNAi agent (Phio Pharmaceuticals)

N/A

Report date: 2025/01/26 16:36:21
NME

Base Information

Drug NameCBLB-silencing RNAi agent (Phio Pharmaceuticals)
Drug Alias NameCBL-B checkpoint inhibitor (Phio Pharmaceuticals)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionE3 ubiquitin-protein ligase CBL-B expression inhibitors
TargetsE3 ubiquitin-protein ligase CBL-B
Therapy Area/IndicationsHematologic NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPhio Pharmaceuticals Corp
China Registration ClassN/A

Develop Information

Active CompaniesPhio Pharmaceuticals Corp
Inactive CompaniesN/A
Active IndicationsHematologic Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A